864782-17-2

Upstream product

• 909414-36-4 Biphenyl-2-ylcarbamic Acid 1-[2-(5-aminopentylcarbamoyl)ethyl]piperidin-4-yl Ester 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 909414-35-3 biphenyl-2-ylcarbamic acid 1-{2-[5-(4-hydroxybenzylamino)pentyl-carbamoyl]ethyl}piperidin-4-yl ester mononapadisylate ethanolate 
• 864783-32-4 biphenyl-2-ylcarbamic acid 1-{2-[5-(4-hydroxybenzylamino)pentyl-carbamoyl]ethyl}piperidin-4-yl ester 1,5-naphthalenedisulfonic acid salt 

Relevant academic research and scientific papers

Crystalline forms of a biphenyl compound

The invention provides crystalline naphthalene-1,5-disulfonic acid salts of biphenyl-2-ylcarbamic acid 1-{2-[5-(4-hydroxybenzylamino)pentylcarbamoyl]ethyl}piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The invention also provides pharmaceutical compositions comprising the crystalline compounds or prepared using such compounds; processes and intermediates for preparing the crystalline compounds; and methods of using the compounds to treat pulmonary disorders.

Biphenyl compounds useful as muscarinic receptor antagonists

This invention provides compounds of formula I: wherein a, b, c, m, p, r, R1, R2, R3, R4, R5, R6, W and X1 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.